Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




PCR Test Detects Co-Infection by Novel Species of Parasite in Severe Cases of Visceral Leishmaniasis

By LabMedica International staff writers
Posted on 03 Nov 2023

Leishmaniasis remains an overlooked health concern worldwide, with Brazil experiencing an increase in the number of individuals co-infected by the protozoans Leishmania infantum and Crithidia. More...

The most serious form of the disease, visceral leishmaniasis (VL), targets vital organs such as the spleen and liver, and if not correctly identified and treated, can be fatal. L. infantum is the primary cause of VL, and health professionals in VL-prevalent regions of Brazil are observing a spike in cases of co-infection by both L. infantum and Crithidia, the latter traditionally seen as a non-human-infecting mosquito parasite. Current diagnostic methods fall short of providing a clear picture due to the absence of simple, specific tests. Now, a new test can accurately identify the causative agent in less than two hours, enabling targeted treatment.

Researchers from the Federal University of São Carlos (UFSCar, São Carlos, Brazil) have developed a PCR test that analyzes the genetic material from samples and generates results quickly, in under two hours, thereby enhancing the detection process for the pathogens causing severe VL. This new approach represents a significant improvement over existing diagnostic tests that only recognize antibodies rather than the actual pathogens. The dye-based quantitative PCR assay, developed by the researchers, targets specific sequences from both L. infantum and Crithidia, which are found in experimental and clinical samples. Previously, two separate tests were necessary—one for each pathogen—but now, any laboratory equipped to conduct qPCR tests (which have become more common due to the COVID-19 pandemic) can perform this test. The test can also be a valuable tool for epidemiological studies, monitoring parasite levels, and checking the effectiveness of treatments.

In their research, the new test demonstrated high accuracy in detecting and quantifying both L. infantum and Crithidia in various samples, including those from humans and animals like dogs, cats, and even insects, whether through skin biopsies or bone marrow aspirations. The study analyzed 62 parasites from the tissues of VL patients, with 51 indicating the presence of Crithidia. Furthermore, the dual infection of Crithidia and L. infantum was discovered in two recent VL cases in Brazil. The researchers emphasize not only the test's accuracy but also suggest that Crithidia infection may be more common than previously understood and that co-infections with both parasites are particularly associated with the most severe cases of the disease.

“Although there are other molecular methods for identifying species, they require DNA sequencing of the sample, which is laborious, slow and expensive. Our test analyzes the parasite’s genetic material directly from vectors and human or animal tissue,” said Sandra Regina Costa Maruyama, a professor of evolutionary genetics and molecular biology at UFSCar. “Identifying the species of parasite correctly ensures that appropriate measures can be taken quickly to prevent progression of the patient’s clinical condition, potentially reducing mortality. It also points to the possible development of more specific drugs and treatments in the future.”

Related Links:
UFSCar 


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Aspiration System
VACUSAFE
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Automated Urinalysis Solution
UN-9000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A large, international study led by City of Hope found that the new, investigational liquid biopsy, called PANXEON, was highly sensitive in detecting stage 1 and 2 pancreatic cancer and had a low rate of false positives. The test was also able to identify high-grade dysplasia, a precancerous condition of the pancreas, potentially enabling intervention before cancer develops. (Photo courtesy of City of Hope)

Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection

Pancreatic cancer has the lowest survival rates of any cancer, with only 14% of patients alive five years after diagnosis. The disease is typically discovered after it has spread, and an estimated 90%... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Pathology

view channel
image Credit: iStock

Tumor Budding Grading May Predict Chemotherapy Benefit in Resected Lung Squamous Cancer

Outcomes after resection for lung squamous cell carcinoma (SqCC) vary substantially, and the uneven benefit of adjuvant chemotherapy complicates postsurgical treatment decisions. Pathologic markers that... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.